Back to Multiple Sclerosis

NCT07282574

NCT07282574
Recruiting Phase 2 🇦🇺 Australian site

Who may be able to join

Who might be able to join this trial:

  • You have been diagnosed with Progressive Multiple Sclerosis (MS), confirmed using a specific set of medical guidelines called the 2017 McDonald criteria
  • Your level of physical disability, as measured by a standard MS scoring scale, falls within a moderate range (between 3.0 and 6.0 on this scale — confirm with trial site if unsure of your score)

Who may not be able to join:

  • You have had an MS relapse (a flare-up of symptoms) in the 6 months before joining the trial
  • Doctors are unable to access a vein in your arm or hand for injections or blood draws
  • You have a history of alcohol or drug misuse within the past 5 years, based on the doctor's assessment
  • You are unable to have an MRI scan for any reason
  • You have a medical reason that prevents you from taking certain medications that must be given alongside the trial treatment (confirm with trial site)
  • You have received a treatment called intravenous immunoglobulin (a blood-derived therapy given through a drip) or a blood-filtering treatment called plasmapheresis within the 12 weeks before joining the trial

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Hoffmann-La Roche
Registry
clinicaltrials_gov
Start date
10 March 2026
Est. completion
30 May 2028

Where this trial is recruiting

🇦🇺 Australia 🇫🇷 France 🇩🇪 Germany 🇭🇺 Hungary 🇮🇹 Italy 🇳🇿 New Zealand 🇵🇱 Poland 🇵🇹 Portugal 🇪🇸 Spain Turkey (Türkiye) 🇬🇧 United Kingdom

4 site(s) in Australia. Confirm current status and contact details directly with the trial site.

Primary endpoints

Time From Randomization to the First Occurrence of Composite Confirmed Disability Progression (cCPD) Confirmed for at Least 12 Weeks (cCDP12)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 30 June 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

View original record on ClinicalTrials.gov